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Abstract
Apolipoprotein E (apoE) plays a crucial role in lipoprotein
metabolism both in plasma and in peripheral tissues. To
test whether apoE in the vascular wall has a direct and
local effect on atherogenesis, we established transgenic mice
expressing human apoE under control of H2 Ld promoter.
Studies on mRNA levels and immunohistochemistry demon-
strated that this line was characterized by high expression
of human apoE in the arterial wall while its expression was
relatively low in other tissues as compared with the respec-
tive endogenous expression of mouse apoE. They showed no
difference in plasma cholesterol levels and lipoprotein pro-
file from controls when fed both normal and atherogenic
diets. However, after 24 wk of an atherogenic diet, the for-
mation of fatty streak lesions in proximal aorta was mark-
edly inhibited in transgenic mice as compared with controls.
Both lesion area and esterified cholesterol content were
< 30% of those in controls. In a tissue cholesterol labeling
study with 3H-cholesterol, the specific activity of aorta cho-
lesterol was much less in transgenic mice, suggesting that
apoE enhances cholesterol efflux from the aortic wall into
plasma. Thus, apoE has anti-atherogenic action which is
mediated via enhancing reverse cholesterol transport from
arterial wall. (J. Clin. Invest. 1995.95:469-476.) Key words:
atherosclerosis * cholesterol * lipoprotein - vascular wall.
H2 antigens
Introduction
Apolipoprotein E (apoE), a major component of plasma lipopro-
teins, has a high affinity for low density lipoprotein (LDL)
receptors and putative chylomicron remnant receptors (1, 2).
Through its interaction with these receptors mainly in the liver,
apoE regulates plasma clearance of lipoproteins containing apo-
lipoprotein B such as very low density lipoprotein (VLDL),
intermediate density lipoprotein (IDL), and LDL (3-11). Re-
cently, we have established transgenic mice which overexpress
rat apoE in the liver and have high plasma apoE levels (12).
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They showed a marked reduction in plasma lipids due to elimi-
nation ofplasma VLDL and LDL, and resistance to diet-induced
hypercholesterolemia (13, 14). In this transgenic line, no fatty
streak lesions were found in the aorta after a 10-mo atherogenic
diet, while controls exhibited significant lesions (unpublished
observation). In contrast, it was reported that apoE deficient
mice produced by gene-targeting showed marked increases in
VLDL and IDL cholesterol, and developed spontaneous athero-
matous lesions in the aorta (15, 16). These findings suggest that
apoE facilitates plasma clearance of apoB-containing lipopro-
teins which in the absence of apoE accumulate in plasma as
atherogenic lipoproteins and cause atherosclerosis. Meanwhile,
we have reported that sustained intravenous injection of apoE
inhibited progression of atheroma in Watanabe Heritable Hyper-
lipidemic rabbits, LDL receptor-deficient animals (17). Interest-
ingly, there was no significant difference at steady state in the
plasma cholesterol levels of the apoE injection group and the
saline injection group as controls. Thus, the data suggest that a
low dose of apoE may inhibit process of atherosclerosis by
mechanism(s) other than its plasma cholesterol-lowering activ-
ity. In the present study, we intended production of transgenic
mice expressing apoE in the arterial wall to see a direct and
local effect of apoE on atherogenesis.
Methods
Materials. pKCR containing mouse H2 Ld promotor was kindly pro-
vided by Dr. Miyazaki, J. [1,2,6,7-3H(N)J-Cholesterol, a32P-dCTP, and
y32P-ATP were purchased from DuPont-New England Nuclear Re-
search Products (Boston, MA). Moloney murine leukemia virus
(MMLV) reverse transcriptase was from Promega (Madison, WI). Taq
DNA polymerase was from Perkin Elmer Cetus, Roche Molecular Sys-
tems, Inc., (Branchburg, NJ). C57BL/6 mice were from Nippon Bio-
supp. Inc. (Tokyo, Japan). Restriction enzymes were from Boehringer
Mannheim GmbH, Biochemica, (Mannheim, Germany). All reagents
used were of analytical grade.
Production of transgenic mice. For construction of DNA for micro-
injection, the SV40 promotor region of the expression vector, pKCR3
(18), was replaced by mouse H2 Ld promotor (19, 20). pKCR3 is a
pBR322-based plasmid which contains a small portion of second exon,
second intron, third exon and 3' noncoding region with polyadenylation
site of rabbit /-globin gene (21). Human apoE cDNA (E3) was inserted
into EcoRI site in the third exon of rabbit 63-globin gene. The SphI
XhoI fragment of the fused plasmid, as represented in Fig. 1, was
excised after agarose-electrophoresis, purified by extraction with phenol
and chloroform, and used for microinjection. Transgenic mice was pro-
duced as previously described (12) except that the fertilized eggs of
C57BL/6 were used. Newborn mice were screened for integration of
the transgene by polymerase chain reaction (PCR) of tail DNA (1 gLg)
with 5' primer in ,B-globin gene (5'-ACATCCTGGTCATCATCCTG-
3') (21) and 3' primer in human apoE cDNA (5'-AAAGCGACCCAGT-
GCCAGTT-3') (22) in 1X PCR buffer (50 mM KCl, 1.5 mM MgCl2,
10 mM Tris-HCl, pH 8.3), 100 ,M dNTPs, and 2 U of Taq polymerase.
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Figure 1. DNA construct for microinjection. The DNA used for microin-
jection was constructed using expression vector, pKCR3 (18) so that in
vivo expression of human apoE cDNA (closed box) would be transcribed
under control of mouse H2 Ld promotor (stippled box) (19) with splicing
the intron of rabbit ,/-globin gene (open boxes). The exons derived from
rabbit /3-globin gene are shown as thick open box. The intron and 3'
noncoding region containing polyadenylation site are shown as thin
open box. This construct was microinjected into fertilized eggs of
C57BL/6 to generate transgenic mice.
After the 30th cycling reaction of heat to 940C for min (denature),
630C for 2 min (anneal), and 720C for 3 min (extend), the targeted
sequence (330 bp) which is specific to the transgene, was amplified.
One of the two positive lines was designated as Hae 1-14 and used for
the following experiments. By Southern blotting of tail DNA with the
probe of human full-length cDNA, the integrated gene was estimated
to be ten copy. The inheritance pattern was compatible with a single
autosomal integration site.
Preparation of total RNA and blot hybridization with apoE probes.
Total RNA was isolated from each tissue of transgenic mice and non-
transgenic littermates by extraction with acid guanidinium thiocyanate,
phenol and chloroform (23). 1 Htg of total RNA from arterial walls
and 10
.tg from other tissues were subjected to electrophoresis in a
formaldehyde-agarose (1%) gel, and transferred to a nylon membrane.
The filter was hybridized with a probe of full-length human apoE cDNA
labeled by random primer method with a32P-dCTP. As shown in the
lanes of liver RNA in Fig. 2, this probe detected both mouse and human
apoE mRNA. In some experiments, human apoE-specific oligonucleo-
tide probe (5'-ATGGCTGCAGGCTTCGGCGTTCA-3') and mouse
apoE-specific oligonucleotide probe (14) were used after 5' end labeling
with y32P-ATP.
Differential reverse transcriptased (RT)-PCR. Ratio of human apoE
mRNA level to total (human and mouse) apoE mRNA level was esti-
mated by differential RT-PCR method as follows. First strand cDNA
was synthesized from Mg of total RNA from each tissue by incubation
at 37°C for 60 min with MMLV reverse transcriptase in1X PCR buffer,
200 MM dNTPs, 10 mM DTT, RNase inhibitor (2 units) and 20 pmol
of the 3' outer primer (5'-CTTGAGGCGGGCCTGGAA-3'). The mix-
ture was subjected to PCR with 20 pmol of the 5' primer (5'-TACCTGC-
GCTGGGTGCAGAC-3') and 3' inner primer (5'-ACCGCGCTC-
GGCGCCCTCGCG-3') in IX PCR buffer, 10% DMSO, 100 MM dNTPs
with 30 times cycling reaction of heat to 94°C for min, 60°C for 2
min, and 72°C for 3 min. This reaction amplified 681-bp fragments
derived from both human or mouse apoE cDNA. Since nucleotide se-
quences of three primers used here were completely identical between
human and mouse apoE cDNA (22, 24), the relative amounts of target
sequences derived from mouse and human apoE mRNAs were the same
as those of both original mRNAs. The RT-PCR products derived from
human and mouse apoE mRNA could be separated by digestion with
Sau3AI whose sites were found only in mouse sequence of the products.
The ratios were estimated by comparison of the densities of the bands
of the products with or without Sau3AI digestion on 1.5% agarose
after electrophoresis and ethidium bromide staining. The linearity of
quantitation under the range of estimation was confirmed by the mixing
experiment with total RNA of mouse liver and HepG2 cells as mouse
and human apoE mRNA sources, respectively.
Immunohistochemical studies. The heart and attached aorta were
resected from transgenic and control mice at 24 wk of age, immersed
in saline for h, and immediately fixed in 4% paraformaldehyde in
phosphate buffer saline, pH. 7.4. The paraformaldehyde-fixed, paraffin-
Liver Aorta Figure 2. Blot hybridiza-
tion of total aortic RNA
from transgenic mice
with human apoE cDNA.humnan apoE * Total RNA isolated
mouse apoE from each tissue of
transgenic mice (tg) and
cont tg cont tg
nontransgenic littermates
(cont). In this line, inte-
gration of the transgene was confirmed by PCR and Southern blot analy-
ses. 1 HIg of total RNA from aorta and 10 qg of total RNA from liver
were subjected to electrophoresis in a formaldehyde-agarose (1%) gel,
and transferred to a nylon membrane. The filter was hybridized with a
probe of human apoE cDNA. As shown in the lanes of liver RNA, this
probe detected both mouse and human apoE mRNA. Transgenic and
control mice had a similar level of endogenous mouse apoE mRNA,
while transgenic mice expressed human apoE mRNA of a slightly longer
length from the transgene.
embedded sections of the materials were subjected to immunohisto-
chemistry as previously described (25). The primary antibodies used
were a goat anti-human apoE antibody at 1:200. Bound primary anti-
body was detected by incubation with biotinylated horse anti-goat IgG
at 1:200 followed by incubation with peroxidase-conjugated strepta-
vidin.
Atherogenic diet. Female transgenic mice and nontransgenic lit-
termates were housed in the same cages and fed the same diet at the
same time. There was no significant difference in the body weights
between the transgenic and control groups. For atherogenic diet group,
atherogenic diet was given to 11 transgenic and control mice at 12 wk
of age. The atherogenic diet contains 15% (wt/wt) fat (cocoa butter),
1.25% (wtlwt) cholesterol, and 0.5% (wt/wt) sodium cholate (26). For
normal diet group, normal mouse chow was continued. After 24 wk of
the atherogenic diet, blood was drawn from retroorbital plexus to mea-
sure plasma cholesterol levels. Animals on the atherogenic diet were
sacrificed for evaluation of aortic atheroma.
Estimation of fatty streak lesions in aorta. After the atherogenic
diet, the heart and attached aorta were resected, placed in 0.9% saline
for 1 h, and incubated in 7% formalin for 48 h. After 48 h in an O.C.T.
compound embedding medium, each sample was frozen on a cryostat,
and 10-Lm cross-sections were made beginning with the lower portions
of atria. All sections were examined by microscopy without any stain.
Four sections, each separated by 60 gm, were used to evaluate the
lesions: two sections at the end of aortic sinus and two sections at the
junctional site of the sinus and ascending aorta, which were determined
by presence of three valve cusps, and a rounded aorta where the lesions
were reproducibly most prominent. Fatty streak lesions were stained by
Oil Red 0 and haematoxylin. The area of each section was determined
by weighing the lesions excised from the enlarged photocopies of a
photograph of the section in microscopy. The mean lesion area per
section per animal was calculated for each group of animals (n = 6).
Measurement of cholesterol content of the aorta. In another set of
transgenic and control mice subjected to the atherogenic diet, the heart
and attached aorta were resected and placed in 0.9% saline for1 h. The
heart and surrounding soft tissues were carefully removed. Thoracic and
abdominal portions of the aorta were weighed. Lipids were extracted
with chloroform/methanol using Folch's method (28). Esterified and
unesterified cholesterol contents were measured as described previ-
ously (14).
Assays. Plasma cholesterol was measured by enzymatic method (27)
and plasma human apoE level was determined by immunoturbid assay.
Mouse apoE level of control mice was not detectable by this assay.
For determination of cholesterol levels in lipoprotein fraction, a pooled
plasma sample from each group was subjected to gel filtration chroma-
tography (HPLC) as previously described (13). Cholesterol levels of
each lipoprotein fraction were determined from the area under the curve
of monitoring.
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mouse H2 Ld promc
SphI
A B
C
CFigure 3. Immunohistochemistry of
aortae with anti-human apoE anti-
body. The heart and attached aorta
were resected from transgenic (A
and C) and control mice (B), and
were immediately subjected to im-
munohistochemistry with anti-hu-
man apoE polyclonal antibody as
described in Methods. A and B,
cross sections; C, longitudinal sec-
tion. x400.
Cholesterol labeling study with 3H-cholesterol. Transgenic and con-
trol mice at 12 weeks of age were given atherogenic diet containing
[1,2,6,7-3H(N)]-Cholesterol (1 mCi/1 g cholesterol, - 30 pCi/mouse)
for 2 d. Then, the diet was switched to the atherogenic diet without
radioisotopes. After three and seven weeks of the atherogenic diet, the
animals (n = 7) were sacrificed. Blood was drawn and each tissue was
resected. Cholesterol was extracted from plasma and each tissue using
Folch's method (28). The cholesterol content and radioactivity of each
sample were measured. The ratio of specific activity (dpmlmg choles-
terol) in aorta and other tissues to that in plasma was calculated in each
animal.
Results
In mice, susceptibility to diet-induced atheroma differs in the
degree from strain to strain. C57BL/6, which is well known to
be most susceptible (29), was used to produce apoE transgenic
mice. DNA construct used for microinjection was human apoE
(E3) cDNA under control of mouse H2 Ld promotor (Fig. 1).
H2 Ld, the MHC class I antigen, is expressed ubiquitously in
many tissues of mice after late embryonal stage (30). Thus,
under control of this promoter, expression of apoE could be
expected in arterial wall and the possibility could be excluded
that ectopic expression of the transgene might affect organogen-
esis in embryonal stage. A line, designated HAE 1-14, had 10
copies of the transgene in the estimation of the Southern blot
analysis on tail DNA. Northern blot analysis using human apoE
cDNA probe demonstrated that human apoE mRNA was found
in the aortic wall from transgenic mice (Fig. 2). In contrast, no
apoE mRNA was detectable in the aorta from nontransgenic
control on this method, although this probe also hybridized
mouse apoE mRNA as shown in liver RNA. Immunohistochem-
istry with anti-human apoE antibody demonstrated that human
apoE protein was detected in endothelial cells and medial
smooth muscle cells in the aortic wall of the transgenic mice
while undetectable in controls (Fig. 3). Furthermore, even in
another line of transgenic mice which overexpressed apoE in
the liver and not in the artery, and had very high plasma apoE
level (12), we could not detect apoE in the artery by the same
procedure using rat apoE antibody. Therefore, immunoreactive
human apoE in the arterial wall in transgenic mice in this study
was produced in situ and not derived from plasma.
On Northern blot analysis using human apoE-specific probe,
small, but considerable amounts of human apoE mRNA levels
were detected in many other tissues such as liver, lung, spleen,
intestine, heart, muscle (Fig. 4 B), and peritoneal macrophage
(data not shown), which also endogenously express mouse
apoE. To estimate human and mouse apoE mRNA levels sepa-
rately, differential RT-PCR method was developed and relative
mRNA levels in each tissue were calculated. As shown in Fig.
4 C, human apoE mRNA levels in every tissues except arterial
wall were relatively low as compared to mouse endogenous
levels. By contrast, since the RT-PCR products from aortic wall
was almost all derived from human apoE mRNA, the ratio in
this tissue was 1.0, which was consistent with the result from
Northern blot analysis (Fig. 2). Consistently, plasma human
apoE level of transgenic mice was only 0.85 mg/dl, while mouse
apoE levels in both groups were estimated to be 3-4 mg/dl.
The ratio of human plasma apoE level to mouse plasma apoE
level was in accordance with the mRNA ratio in the liver, which
was likely major source of plasma apoE. Furthermore, Northern
blot analysis using mouse apoE specific probe which did not
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Figure 4. Expression of hu-
man apoE mRNA in differ-
ent tissues. (A) Blot hybrid-
ization of total RNA with hu-
man apoE cDNA. (B) Blot
hybridization of total RNA
with human apoE specific
oligo probe. (C) ApoE
mRNA ratio ( human/human
and mouse ) estimated by
differential RT-PCR. 10 pg
of total RNA from each tis-
sue was subjected to blot hy-
bridization with human apoE
cDNA (A). Thereafter, the
filter was dehybridized and
reprobed with human apoE
specific oligo probe (B). 1 Ig
of total RNA from each tis-
sue was also used for differ-
ential RT-PCR to estimate
human apoE and mouse
apoE mRNA levels sepa-
rately. Ratio of human apoE
mRNA level to total (human and mouse endogenous) mRNA level
in each tissue was shown (C). The values were obtained from two
independent experiments using six animals. The value in aortic wall
was 1.0 since almost all RT-PCR product was derived from human
apoE mRNA.
hybridize with human apoE mRNA showed that mouse apoE
mRNA level in each mouse apoE-expressing tissue was not
significantly different between transgenic and control mice (data
not shown). These data indicate that this line expresses human
apoE characteristically in the arterial wall, and that, in other
tissues and in plasma, apoE expression was similar to control
mice. Thus, it could be concluded that this line was a good
model for evaluation of local function of apoE in the arterial
wall.
For analysis of diet-induced atheroma, atherogenic diet con-
taining high cholesterol and fat was given to transgenic mice
and non-transgenic controls. After 24 wk, proximal aortic sec-
tions were stained with Oil-red 0 and formation of fatty streak
lesions were compared. Representative microscopies of the le-
sions were shown in Fig. 5. The fatty streak lesions were much
smaller (30% in area) in transgenic mice than in controls (Fig.
6). As shown in Fig. 5, the lesions were found in both aortic
wall and valve cusps. Fatty streak lesions in cusps were reported
not to be correlated to those in arterial walls, not to be reproduc-
ible, and thus recommended to be excluded from estimation
(31). When the lesions under consideration were restricted to
aortic walls and did not include valve cusps, the difference in
lesion area was much more prominent (15% of controls) since
the lesions in cusps were similar between the two groups (Fig.
6). The contents of cholesterol in whole thoracic and abdominal
portions of aorta were measured (Fig. 7). The esterified choles-
terol content was much less in transgenic mice than in controls,
while there was no significant difference in the total cholesterol
content. The data indicated that apoE expressed in the arterial
wall had an inhibitory effect on formation of diet-induced early
atherosclerosis. Qualitative aspects of the fatty streak lesions in
aortic wall, such as foamy macrophages, were similar between
the two groups.
There were no significant differences in plasma cholesterol
levels between the transgenic mice and controls on both normal
and atherogenic diets (Table I). Analysis of lipoprotein fraction
by gel filtration chromatography demonstrated that two groups
had similar patterns of lipoprotein cholesterol profile. The ath-
erogenic diet caused a marked increase in non-HDL (VLDL and
LDL) cholesterol and a profound decrease in HDL cholesterol in
both groups. Thus, the inhibitory effect of apoE on the formation
of fatty streak lesions in transgenic mice was not attributed to
plasma cholesterol level and profile.
To know the mechanism by which transgenic mice have
smaller fatty streak lesions, efflux of cholesterol from arterial
wall to plasma was estimated. 3H-cholesterol was orally given
to animals on atherogenic diet for 2 d to label tissue cholesterol,
followed by atherogenic diet without 3H-cholesterol. Prelimi-
nary data showed that time-coursed changes in specific activity
of plasma cholesterol were almost identical between the two
groups and that 1 wk after administration of labeled cholesterol,
the value was decreased to < 5% of the initial value at the
cessation of administration of 3H-cholesterol. 3-7 wk after the
administration, half of animals in each group (n = 7) were
sacrificed and specific activities of cholesterol in plasma, aortic
wall and other tissues were measured. To exclude variations of
data among animals of each group mainly because of differences
in intestinal absorption of radiolabeled cholesterol, the ratio of
the specific activity in each tissue vs. in plasma was calculated.
As shown in Table II, after the interval of 3 wk, the ratio values
of transgenic and control mice in each tissue were similar. The
ratio of specific activities of aortic wall vs. plasma in transgenic
and control mice were < 1.0 while the values of the two groups
in other tissues were 1.0 or more, suggesting that incorporation
of labeled cholesterol from plasma into aortic wall was rela-
tively slow as compared to those into other tissues. This was
consistent with previous report on the tissue cholesterol labeling
studies with rabbits (32) 7 wk after the administration, when
the specific activities in aortic walls of both groups were higher
than those in plasma, the ratio of aortic wall vs. plasma was
significantly lower in transgenic mice than in controls (P
< 0.05). The data suggest that cholesterol efflux from aorta was
enhanced in transgenic mice. At this interval, other tissues in
transgenic mice also had lower ratios than in controls, although
not significant.
Immunohistochemical staining of apoE in the aortic sinus
from transgenic mice after the atherogenic diet was shown in
Fig. 8. Marked staining of apoE was found in the advanced
atheromatous lesions (Fig. 8 A) as well as apparently normal
area of arterial wall (Fig. 8 B). Immunoreactive apoE in the
lesions was localized mainly in the extracellular matrix.
Discussion
Since apoE was found in the atheromatous lesions, it has been
thought to be involved in atherogenesis (33-35). Our present
data suggest that apoE localized in the arterial wall has anti-
atherogenic function. While apoE expression under control of
Ld promotor in this transgenic mice was found ubiquitously in
many tissues, the difference between the transgenic and control
groups was only prominent in arterial wall. Thus, this line is a
good model for analysis on the effects of apoE produced locally
in the arterial wall.
Dramatic inhibition of diet-induced atheroma was demon-
strated in transgenic mice. Diet-induced atheroma in mice has
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Figure 5. Fatty streak lesions in proximal aorta and aortic sinus after atherogenic diet. After 24 wk of atherogenic diet, the hearts and aortae of
transgenic mice and nontransgenic littermates were resected for evaluation of fatty streak lesions. Representative microscopies of the three different
cross sections after Oil Red 0 and haematoxylin staining are shown: the aortic sinus (B and C) and the junctional site of aortic sinus and proximal
aorta (A). x 140.
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30000 Figure 6. Areas of fatty[ cusps streak lesions in aortae
E * after atherogenic diet.
=t i lFatty streak lesions by
20000 Oil Red 0 staining in
0 aortic sinus and proximalH
aorta were measured as
described in Methods.loooo
T The mean lesion area per
0 | section per animal was
calculated for each groupo- _ of animals (n = 6). Le-
control transgenic sions in the aortic wall
(closed column) and in
the valve cusps (open column) were separately measured. The mean
total lesion areas in transgenic and control mice were 7130±1692 (S.D.
as bars) and 23460+6639 tzm2, respectively (significant at P < 0.001).
Lesion areas in the aortic wall in transgenic and control mice were
2876±1904 and 19580+6145 ,Im2, respectively (significant at P
< 0.001). Those in the valve cusps in transgenic and control mice were
3879±+1430 and 4253±+1682 /Im2.
been reported to be associated with atherogenic changes in
plasma lipoprotein cholesterol profile such as increases in apoB
containing lipoproteins or decrease in HDL cholesterol, which
were observed in both groups in this study. There were no
differences in these values between transgenic and control mice,
therefore, the effect of apoE on the process of atherosclerosis
is not related to plasma cholesterol level. In this respect, the
observations are similar to those in the previous report on inhibi-
tion of progression of atheroma in WHHL rabbits by chronic
intravenous injection of purified apoE (17). While the injected
apoE into WHHL rabbits exerted its effect on arterial wall via
plasma, apoE produced in situ had anti-atherogenic action in
transgenic mice in the current study. The mechanisms of this
anti-atherogenic action implicate some unknown aspects of
apoE functions in vivo.
ApoE has been reported to play a role in redistribution of
lipids in peripheral tissues (1) and contribute to reverse choles-
terol transport in which extra-cholesterol in peripheral tissues
is transported to the liver (36-38). Apo E can promote efflux
of cholesterol from cholesterol-loaded cells in vitro as well as
apolipoprotein AI (39). Thus, the extracholesterol accumulating
1. 5 - Figure 7. Esterified cho-
H lesterol contents of the0H T aorta after atherogenic
diet. In another set of
en@H4 1. 0 transgenic and controlo mice subjected to athero-
genic diet, thoracic and
abdominal portions of
the aorta in each animal
44 U were resected and
weighed. Lipids were ex-
V tracted, esterified and un-
. oesterified cholesterol
control tranagenic contents were measured
as described previously
(12). Mean esterified cholesterol contents of transgenic and control mice
were 0.44±0.22 (S.D. as bars), 1.23+0.10 ,ug/mg-tissue, respectively
(significant at P < 0.05, n = 5). Unesterified cholesterol contents were
5.50+0.74, 5.22+0.56 jig/mg-tissue, respectively.
Table L Plasma Cholesterol Profile in Transgenic
and Control Mice
Cholesterol levels
Human
apoE Total VLDL LDL HDL
Normal chow diet
Controls 86±11 2.9 21 62
Transgenics 0.85±0.17 85±11 2.9 20 62
Atherogenic diet
Controls 146±39 9.1 117 20
Transgenics 1.2±0.43 142±25 7.0 110 25
Values are expressed as mean±SD (mg/dl, n = 11). Cholesterol levels
in plasma lipoprotein fractions were determined from pooled plasma.
in the subendothelial foam cells can be transported with apo E
to the liver, where it is removed by receptor-mediated endocyto-
sis. The data on tissue cholesterol labeling study with 3H-choles-
terol suggest that apoE promotes cholesterol efflux from apoE-
producing tissue, especially arterial wall, to plasma and that
anti-atherogenic action of apoE observed in this study may be
mediated via this action. In transgenic mice on atherogenic diet,
not only normal vascular cell components such as endothelial
cells and medial smooth muscle cells, but also macrophages in
the fatty streak lesion could express human apoE and contribute
to enhanced cholesterol efflux from the arterial wall to protect
fatty streak lesions. In early process of atherogenesis, it may
determine the fate of lesions whether or not apoE in the lesion
was abundant sufficiently to fully exert anti-atherogenic action.
Table II. Ratio of Specific Activity of Tissue Cholesterol
vs. Plasma Cholesterol in Each Tissue after Oral Administration
of 3H-Cholesterol
After administration of 3H-cholesterol
Three weeks Seven weeks
Tissue Transgenics Controls Transgenics Controls
Aortic wall 0.61±0.05 0.65±0.11 1.98±0.80* 3.75±0.60
Liver 1.60±0.08 1.62±0.18 1.55±0.21 1.50±0.05
Lung 1.09±0.04 1.00±0.03 1.26±0.02 1.39±0.08
Spleen 1.10±0.08 1.31±0.13 1.22±0.10 1.37±0.17
Intestine 1.06±0.14 1.13±0.09 0.72±0.02 0.81±0.04
Heart 1.12±0.16 1.10±0.09 1.08±0.14 1.25±0.01
Muscle 1.28±0.13 1.62±0.12 1.46±0.09 1.67±0.16
Kidney 1.94±0.21 2.21±0.12 1.57±0.31 2.21±0.31
Female transgenic and control mice were given atherogenic diet con-
taining 3H-cholesterol (1 mCi/l g cholesterol) for 2 d to label tissue
cholesterol. Then, the diet was switched to atherogenic diet without
radioisotopes. 3 and 7 wk later, animals in each group were sacrificed,
tissue cholesterol in each tissue (including plasma) was extracted, and
specific activity (dpm/mg-tissue cholesterol) was measured. Specific
activity in each tissue/specific activity in plasma was calculated in each
animal. The value of plasma specific activity in each animal three and
seven weeks after administration of 3H-cholesterol was ranged 46,400-
80,500 dpm/mg, 4,100-7,200 dpm/mg, respectively, and showed no
significant difference between transgenic and control mice. Values are
expressed as mean+SE, n = 7. * P < 0.05 as compared with controls.
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Figure 8. Presence of immunoreactive apoE in aort
mice after atherogenic diet. Some sections of aortic
transgenic mice after 24 wk of atherogenic diet wei
with anti-human apoE antibody. Adjacent section w
Red 0 . Fatty streak lesions were obvious in the intinr
in B. x400.
Extracellular presence of apoE in the atherom;
be resultant remnants of protective reaction as
rosis rather than a causative agent. Since oti
expressed human apoE also tended to slightly
terol efflux to plasma, there might be some quz
tion between expression of apoE and choles
enhanced cholesterol efflux by apoE expressio
sal among various tissues. Although not statist
there tended to be slightly higher plasma HDL
in transgenic mice on atherogenic diet than in c
This may reflect the enhanced efflux of cholest
mice.
It is also possible that apoE in the arterial N
late some steps in atherogenesis and modulate
by mechanisms other than enhanced choleste
might affect recruitment of plasma monocyte
lesion of atheroma to form foamy macrophag
more, since apoE was proposed to play a roli
and differentiation of lymphocytes and smo(
presence of apoE in the arterial wall might inh
sis by modulating the cellular functions of these cell components
of atherosclerosis (1).
The current study demonstrated that apoE produced locally
in the aortic wall enhanced reverse cholesterol transport and
protected the aorta from diet-induced early atherosclerosis. This
suggests that apoE could be a new therapeutic agent which acts
not only systemically against hyperlipidemia, but also locally
against atherosclerosis.
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